These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 10546121)

  • 21. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R; Lenzi S
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
    Gotto AM
    Am J Cardiol; 2005 Sep; 96(5A):34F-38F. PubMed ID: 16126021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid lowering in post-MI patients with normal cholesterol.
    Lawless C; Force R
    J Fam Pract; 1997 Jan; 44(1):30. PubMed ID: 9010366
    [No Abstract]   [Full Text] [Related]  

  • 24. [How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
    MMW Fortschr Med; 2005 Nov; 147(45):54. PubMed ID: 16320655
    [No Abstract]   [Full Text] [Related]  

  • 25. The case for medical treatment in chronic stable coronary artery disease.
    Nash DT
    Arch Intern Med; 2005 Dec 12-26; 165(22):2587-9, discussion 2593-4. PubMed ID: 16344414
    [No Abstract]   [Full Text] [Related]  

  • 26. [Statins and cardiovascular disease prevention: use and prospective].
    Moulin P
    Nephrologie; 2000; 21(7):379-80. PubMed ID: 11200617
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    DeFilippis AP; Bansal S; Blumenthal RS
    N Engl J Med; 2008 Jan; 358(2):194; author reply 194-5. PubMed ID: 18193527
    [No Abstract]   [Full Text] [Related]  

  • 28. The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
    Drown DJ
    Prog Cardiovasc Nurs; 1996; 11(2):38-9. PubMed ID: 8718962
    [No Abstract]   [Full Text] [Related]  

  • 29. [Despite coronary intervention, the risk remains high: PCI patients need additional protection].
    MMW Fortschr Med; 2004 Jun; 146(24):3. PubMed ID: 15366508
    [No Abstract]   [Full Text] [Related]  

  • 30. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective use of statins to prevent coronary heart disease.
    Crouch MA
    Am Fam Physician; 2001 Jan; 63(2):309-20, 323-4. PubMed ID: 11201696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins & Alzheimer's.
    Feinberg AW
    Health News; 2000 Dec; 6(12):1. PubMed ID: 11142934
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The 4-S study--a turning point in the cholesterol debate. Work Group Lipids and Atherosclerosis of the Swiss Society for Cardiology].
    Nigg C
    Praxis (Bern 1994); 1995 Dec; 84(51-52):1514-6. PubMed ID: 8571010
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    McEvoy JW; Margey R; Blake GJ
    N Engl J Med; 2008 Jan; 358(2):193; author reply 194-5. PubMed ID: 18184967
    [No Abstract]   [Full Text] [Related]  

  • 38. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.